Outcomes of a Routine Screening Protocol to Prevent Metamycoplasma and Ureaplasma Infection in Lung Transplant Recipients
Transplant Infectious Disease · 2026-07 · 28 (4)
DOI: 10.1111/tid.70221 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Transplant Infectious Disease, online erschienen am 05.05.2026. Verfasst von Lalithaa Thirunavukarasu Murugan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, University of Utah Health, Salt Lake City, Utah, USA. Hauptthemen laut MEDLINE: Lung Transplantation, Ureaplasma Infections, Mycoplasma Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Metamycoplasma hominis and Ureaplasma species (Mollicutes) can cause clinically significant Mollicute infections (csMI) early after lung transplantation (LT). Mollicute infection is associated with hyperammonemia syndrome (HS), a complication resulting in cerebral edema and death. We sought to describe the results before and after a screening protocol to detect and preemptively treat Mollicutes early after LT.
Methods
We retrospectively reviewed LT data at our institution before (January 1, 2020–September 4, 2022) and after (September 5, 2022–August 31, 2023) a screening protocol to detect Mollicutes by PCR on bronchoalveolar lavage within 24 h post‐LT and serum ammonia monitoring every 48 h. Antibiotics were initiated for ammonia > 60 µmol/L or if PCR+. We assessed risk factors and recipient outcomes for Mollicute PCR+ and PCR−. We compared the incidence of HS and csMI in the protocol and pre‐protocol groups.
Results
Screening detected Mollicutes in 24/125 (19.2%). All were treated ≥ 14 days. On multivariable analysis, donor age ≤ 40 years was associated with PCR+ (OR: 4.28, 95% CI: 1.65–12.13, p = 0.004). There were no differences in 6‐month mortality (8.3% vs. 7.9%, p = 0.61), 3‐month rejection (46% vs. 37%, p = 0.19), or mean ICU length of stay (35 days [SD = 29] vs. 42 days [SD = 54], p = 0.14) between PCR+ and PCR−. csMI occurred in 1/125 (0.8%) in the protocol group with no HS. Pre‐protocol, 15/1373 (1.09%) developed csMI or HS with two deaths from HS.
Conclusions
Mollicute detection by PCR screened early post‐LT was inversely associated with donor age. Preemptive treatment for Mollicute detection and elevated ammonia in the early posttransplant setting may prevent serious donor‐derived infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, University of Utah Health, Salt Lake City, Utah, USA.
- Department of Pulmonary Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
- Department of Pharmacy, MedStar Washington Hospital Center, Washington, DC, USA.
- Department of Infectious Diseases, Cleveland Clinic, Cleveland, Ohio, USA.
ORCID-Profile: Lalithaa Thirunavukarasu Murugan, Anika Sasidharan Nair, Nabin K Shrestha, Christine E Koval
Zitieren
APA
Murugan, L. T., Nair, A. S., Budev, M. M., Converse, M., Shrestha, N. K., & Koval, C. E. (2026). Outcomes of a Routine Screening Protocol to Prevent Metamycoplasma and Ureaplasma Infection in Lung Transplant Recipients. Transplant Infectious Disease, 28(4). https://doi.org/10.1111/tid.70221
Vancouver
Murugan LT, Nair AS, Budev MM, Converse M, Shrestha NK, Koval CE. Outcomes of a Routine Screening Protocol to Prevent Metamycoplasma and Ureaplasma Infection in Lung Transplant Recipients. Transplant Infectious Disease. 2026;28(4). doi:10.1111/tid.70221
BibTeX
@article{Murugan2026,
author = {Murugan, Lalithaa Thirunavukarasu and Nair, Anika Sasidharan and Budev, Marie M and Converse, Maureen and Shrestha, Nabin K and Koval, Christine E},
title = {Outcomes of a Routine Screening Protocol to Prevent Metamycoplasma and Ureaplasma Infection in Lung Transplant Recipients},
journal = {Transplant Infectious Disease},
year = {2026},
volume = {28},
number = {4},
doi = {10.1111/tid.70221}
}
EUVIMED